{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:05:42Z","timestamp":1792785942222,"version":"4.5.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T00:00:00Z","timestamp":1564185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Health and Labour Sciences Research Grant","award":["H29-seishin-ippan-001"],"award-info":[{"award-number":["H29-seishin-ippan-001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This systematic review and meta-analysis included double-blind, randomized, placebo-controlled trials of brexpiprazole adjunctive treatment (0.5\u20133 mg\/d) for major depressive disorder where antidepressant treatment had failed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The outcomes were the response rate (primary), remission rate (secondary), Montgomery \u00c5sberg Depression Rating Scale score (secondary), Sheehan Disability Scale scores (secondary), Clinical Global Impression\u2013Improvement\/Severity scores, discontinuation rate, and individual adverse events. A subgroup meta-analysis of the data at week 6 compared outcomes by dose &gt;2 mg\/d or \u22642 mg\/d (2 mg\/d is the recommended dose).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 9 studies (n\u2009=\u20093391). Compared with placebo, brexpiprazole (any dose) was superior for response rate (risk ratio [RR]\u2009=\u20090.93, 95% confidence interval [95% CI]\u2009=\u20090.89\u22120.97, number needed to treat\u2009=\u200917), remission rate (RR\u2009=\u20090.95, 95% CI\u2009=\u20090.93\u22120.98, number needed to treat\u2009=\u200925), Montgomery \u00c5sberg Depression Rating Scale score (standardized mean difference =\u2009\u22120.20, 95% CI\u2009=\u2009\u22120.29, \u22120.11), Sheehan Disability Scale score (standardized mean difference\u2009=\u2009\u22120.12, 95% CI\u2009=\u2009\u22120.21, \u22120.04), and Clinical Global Impression\u2013Improvement\/Severity scores but was associated with a higher discontinuation rate, akathisia, insomnia, restlessness, somnolence, and weight increase. Doses &gt;2 mg\/d had a significantly higher RR for response rate than \u22642 mg\/d (0.96 vs 0.89); moreover, compared with placebo, doses &gt;2 mg\/d were associated with higher incidences of akathisia (RR\u2009=\u20094.58) and somnolence (RR\u2009=\u20097.56) as well as were marginally associated with a higher incidence of weight increase (RR\u2009=\u20093.14, P\u2009=\u2009.06). Compared with placebo, doses \u22642 mg\/d were associated with higher incidences of akathisia (RR\u2009=\u20092.28) and weight increase (RR\u2009=\u20094.50).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Brexpiprazole adjunctive treatment is effective for major depressive disorder when antidepressant treatment fails. At 6 weeks, doses \u22642 mg\/d presented a better risk\/benefit balance than &gt;2 mg\/d.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ijnp\/pyz040","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T07:25:37Z","timestamp":1563953137000},"page":"698-709","source":"Crossref","is-referenced-by-count":29,"title":["Brexpiprazole as Adjunctive Treatment for Major Depressive Disorder Following Treatment Failure With at Least One Antidepressant in the Current Episode: a Systematic Review and Meta-Analysis"],"prefix":"10.1093","volume":"22","author":[{"given":"Taro","family":"Kishi","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Sakuma","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuo","family":"Nomura","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Jikei University School of Medicine, Minato-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Mishima","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita-city, Akita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakao","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,7,27]]},"reference":[{"key":"2019112202102286000_CIT0001","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1017\/neu.2018.23","article-title":"A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorder","volume":"31","author":"Bauer","year":"2019","journal-title":"Acta Neuropsychiatr"},{"key":"2019112202102286000_CIT0002","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1080\/14656566.2016.1254188","article-title":"Adjunctive brexpiprazole for the treatment of major depressive disorder","volume":"17","author":"Beyer","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"2019112202102286000_CIT0003","article-title":"REXULTI (brexpiprazole) Drug Approval Package","author":"Food and Drug Administration (FDA)","year":"2015"},{"key":"2019112202102286000_CIT0004","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"GBD","year":"2017","journal-title":"Lancet"},{"key":"2019112202102286000_CIT0005","volume-title":"Manual for the ECDEU Assessment Battery","author":"Guy","year":"1970","edition":"2nd ed."},{"key":"2019112202102286000_CIT0006","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2019112202102286000_CIT0007","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamapsychiatry.2017.4602","article-title":"Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the united states","volume":"75","author":"Hasin","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"2019112202102286000_CIT0008","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011"},{"key":"2019112202102286000_CIT0009","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4088\/JCP.17m12058","article-title":"A randomized, placebo-controlled study of the efficacy and safety of fixed-dose brexpiprazole 2 mg\/d as adjunctive treatment of adults with major depressive disorder","volume":"79","author":"Hobart","year":"2018","journal-title":"J Clin Psychiatry"},{"key":"2019112202102286000_CIT0010","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/03007995.2018.1430220","article-title":"Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study","volume":"34","author":"Hobart","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"2019112202102286000_CIT0011","first-page":"173","article-title":"Adjunctive brexpiprazole and functioning in major depressive disorder: a pooled analysis of six randomized studies using the Sheehan disability scale","volume":"22","author":"Hobart","year":"2018","journal-title":"Int J Neuropsychopharmacol"},{"key":"2019112202102286000_CIT0012","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.4088\/JCP.11r07485","article-title":"Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis","volume":"73","author":"Iovieno","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"2019112202102286000_CIT0013","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/0706743716659417","article-title":"Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments","volume":"61","author":"Kennedy","year":"2016","journal-title":"Can J Psychiatry"},{"key":"2019112202102286000_CIT0014","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/jpet.114.213793","article-title":"Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator","volume":"350","author":"Maeda","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"2019112202102286000_CIT0015","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jad.2016.05.013","article-title":"Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: results from a post-hoc analysis of two randomised controlled trials","volume":"201","author":"McIntyre","year":"2016","journal-title":"J Affect Disord"},{"key":"2019112202102286000_CIT0016","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"Bmj"},{"key":"2019112202102286000_CIT0017","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"key":"2019112202102286000_CIT0018","doi-asserted-by":"crossref","first-page":"g5741","DOI":"10.1136\/bmj.g5741","article-title":"Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins","volume":"349","author":"Naci","year":"2014","journal-title":"Bmj"},{"key":"2019112202102286000_CIT0019"},{"key":"2019112202102286000_CIT0020"},{"key":"2019112202102286000_CIT0021"},{"key":"2019112202102286000_CIT0022"},{"key":"2019112202102286000_CIT0023","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jad.2017.09.054","article-title":"Efficacy of adjunctive brexpiprazole on the core symptoms of major depressive disorder: a post hoc analysis of two pooled clinical studies","volume":"227","author":"Nelson","year":"2018","journal-title":"J Affect Disord"},{"key":"2019112202102286000_CIT0024","volume-title":"Review Manager (RevMan) [Computer program]. Version 5.3","author":"RevMan","year":"2014"},{"key":"2019112202102286000_CIT0025","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/0269881118760661","article-title":"Meta-analysis and review of dopamine agonists in acute episodes of mood disorder: efficacy and safety","volume":"32","author":"Romeo","year":"2018","journal-title":"J Psychopharmacol"},{"key":"2019112202102286000_CIT0026","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1017\/S0033291700035558","article-title":"The inventory of depressive symptomatology (IDS): psychometric properties","volume":"26","author":"Rush","year":"1996","journal-title":"Psychol Med"},{"key":"2019112202102286000_CIT0027","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004850-199606003-00015","article-title":"The measurement of disability","volume":"11","author":"Sheehan","year":"1996","journal-title":"Int Clin Psychopharmacol"},{"key":"2019112202102286000_CIT0028","doi-asserted-by":"crossref","first-page":"e1001403","DOI":"10.1371\/journal.pmed.1001403","article-title":"Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes","volume":"10","author":"Spielmans","year":"2013","journal-title":"Plos Med"},{"key":"2019112202102286000_CIT0029","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.4088\/JCP.14m09689","article-title":"Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study","volume":"76","author":"Thase","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"2019112202102286000_CIT0030","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.4088\/JCP.14m09688","article-title":"Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants","volume":"76","author":"Thase","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"2019112202102286000_CIT0031","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/NDT.S185815","article-title":"Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies","volume":"15","author":"Thase","year":"2019","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2019112202102286000_CIT0032","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/pcn.12615","article-title":"Neuroscience-based nomenclature: what is it, why is it needed, and what comes next?","volume":"72","author":"Uchida","year":"2018","journal-title":"Psychiatry Clin Neurosci"},{"key":"2019112202102286000_CIT0033","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2147\/NDT.S146840","article-title":"Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies","volume":"14","author":"Weiller","year":"2018","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2019112202102286000_CIT0034","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/JCP.0000000000000622","article-title":"Adjunctive brexpiprazole as a novel effective strategy for treating major depressive disorder: a systematic review and meta-analysis","volume":"37","author":"Yoon","year":"2017","journal-title":"J Clin Psychopharmacol"},{"key":"2019112202102286000_CIT0035","doi-asserted-by":"crossref","first-page":"pyv060","DOI":"10.1093\/ijnp\/pyv060","article-title":"Atypical antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysis","volume":"18","author":"Zhou","year":"2015","journal-title":"Int J Neuropsychopharmacol"},{"key":"2019112202102286000_CIT0036","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/j.euroneuro.2015.08.019","article-title":"A review of the current nomenclature for psychotropic agents and an introduction to the neuroscience-based nomenclature","volume":"25","author":"Zohar","year":"2015","journal-title":"Eur Neuropsychopharmacol"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyz040\/30105788\/pyz040.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/22\/11\/698\/31081753\/pyz040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/22\/11\/698\/31081753\/pyz040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T02:11:08Z","timestamp":1574388668000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/22\/11\/698\/5539907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,27]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyz040","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11]]},"published":{"date-parts":[[2019,7,27]]}}}